Helixmith Co. Ltd (084990) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Helixmith Co. Ltd (084990) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.85 Billion ≈ $-1.93 Million USD) by net assets (₩141.52 Billion ≈ $95.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Helixmith Co. Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Helixmith Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Helixmith Co. Ltd carry for a breakdown of total debt and financial obligations.
Helixmith Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Helixmith Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Knafaim
TA:KNFM
|
0.023x |
|
Aniplus Inc
KQ:310200
|
0.106x |
|
Nuveen California Select Tax Free Income Closed Fund
NYSE:NXC
|
-0.014x |
|
Wanshih Electronic Co Ltd
TWO:6134
|
-0.054x |
|
SinoMedia Holding Limited
F:SJY
|
0.010x |
|
Credit Clear Ltd
AU:CCR
|
0.052x |
|
Panstar Enterprise Co.Ltd
KQ:054300
|
0.031x |
|
Great Boulder Resources Ltd
AU:GBR
|
-0.022x |
Annual Cash Flow Conversion Efficiency for Helixmith Co. Ltd (2010–2025)
The table below shows the annual cash flow conversion efficiency of Helixmith Co. Ltd from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see Helixmith Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩141.52 Billion ≈ $95.91 Million |
₩-6.90 Billion ≈ $-4.67 Million |
-0.049x | +58.59% |
| 2024-12-31 | ₩142.04 Billion ≈ $96.26 Million |
₩-16.72 Billion ≈ $-11.33 Million |
-0.118x | +30.11% |
| 2023-12-31 | ₩153.72 Billion ≈ $104.18 Million |
₩-25.89 Billion ≈ $-17.54 Million |
-0.168x | +10.38% |
| 2022-12-31 | ₩216.80 Billion ≈ $146.92 Million |
₩-40.74 Billion ≈ $-27.61 Million |
-0.188x | -10.96% |
| 2021-12-31 | ₩225.35 Billion ≈ $152.72 Million |
₩-38.16 Billion ≈ $-25.86 Million |
-0.169x | +2.54% |
| 2020-12-31 | ₩276.30 Billion ≈ $187.25 Million |
₩-48.01 Billion ≈ $-32.54 Million |
-0.174x | +17.25% |
| 2019-12-31 | ₩195.57 Billion ≈ $132.53 Million |
₩-41.07 Billion ≈ $-27.83 Million |
-0.210x | -108.92% |
| 2018-12-31 | ₩133.87 Billion ≈ $90.72 Million |
₩-13.46 Billion ≈ $-9.12 Million |
-0.101x | -538.11% |
| 2017-12-31 | ₩164.45 Billion ≈ $111.45 Million |
₩-2.59 Billion ≈ $-1.76 Million |
-0.016x | -9.76% |
| 2016-12-31 | ₩170.93 Billion ≈ $115.84 Million |
₩-2.45 Billion ≈ $-1.66 Million |
-0.014x | -188.31% |
| 2015-12-31 | ₩67.20 Billion ≈ $45.54 Million |
₩1.09 Billion ≈ $740.06K |
0.016x | +9598.28% |
| 2013-12-31 | ₩66.97 Billion ≈ $45.38 Million |
₩11.22 Million ≈ $7.60K |
0.000x | +100.30% |
| 2012-12-31 | ₩64.45 Billion ≈ $43.68 Million |
₩-3.58 Billion ≈ $-2.43 Million |
-0.056x | -26.50% |
| 2011-12-31 | ₩49.78 Billion ≈ $33.74 Million |
₩-2.19 Billion ≈ $-1.48 Million |
-0.044x | +12.11% |
| 2010-12-31 | ₩52.72 Billion ≈ $35.73 Million |
₩-2.64 Billion ≈ $-1.79 Million |
-0.050x | -- |
About Helixmith Co. Ltd
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological… Read more